Influenza can have a devastating impact on adults 65 years and older.

Influenza vaccine effectiveness continues to be challenging in this population. This is largely driven by 2 factors:

**Weakened immune system** due to aging and a reduced ability to mount a sufficient protective immune response.

**Strain mismatch**, which occurs when circulating influenza strains do not match the WHO*-selected strains.

*World Health Organization

Choose an adjuvanted vaccine specifically designed for adults 65+

An adjuvant is a substance added to a vaccine to boost the immune response.

Adding MF59® Adjuvant to an influenza vaccine does more than an antigen alone:

- Designed to help strengthen, broaden, and lengthen immune responses in adults 65+
- May be important in the event of a mismatch between the influenza virus strains in the vaccine and the circulating influenza strains

**FLUAD QUADRIVALENT** is the first-and-only adjuvanted quadrivalent seasonal influenza vaccine approved for adults 65+

Formulated with MF59® Adjuvant to boost the immune response to the influenza strains included in the vaccine.

**REIMBURSED BY MEDICARE PART B**

**CPT CODE 90694**

<table>
<thead>
<tr>
<th>Presentation</th>
<th>2020-2021 NDC Carton</th>
<th>2020-2021 NDC Unit-of-Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single-dose (0.5 mL), pre-filled, needleless syringe</td>
<td>70461-120-03</td>
<td>70461-120-04</td>
</tr>
</tbody>
</table>

For more information, please see the Important Safety Information below and accompanying US full Prescribing Information for FLUAD QUADRIVALENT.
INDICATIONS AND USAGE

FLUAD QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

CONTRAINDICATIONS

Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

• If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

• Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

• The immune response to FLUAD QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

• Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

ADVERSE REACTIONS

• The most common (≥10%) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%).

Other adverse events may occur. For a comprehensive list of local and systemic adverse reactions, please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

Before administration, please see the full Prescribing Information for FLUAD QUADRIVALENT.

FLUAD® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

References: